DEVELOGEN ISRAEL LTD has a total of 28 patent applications. Its first patent ever was published in 1994. It filed its patents most often in Israel, EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are GEMMA BIOTECHNOLOGY LTD, CUREDM GROUP HOLDINGS LLC and CUREDM INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Israel | 7 | |
#2 | EPO (European Patent Office) | 6 | |
#3 | United States | 5 | |
#4 | Australia | 3 | |
#5 | Canada | 2 | |
#6 | WIPO (World Intellectual Property Organization) | 2 | |
#7 | Czechia | 1 | |
#8 | Japan | 1 | |
#9 | New Zealand | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Organic fine chemistry | |
#5 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Yechezkel Tamar | 8 |
#2 | Livnah Nurit | 8 |
#3 | Hornik Vered | 5 |
#4 | Gellerman Gary | 5 |
#5 | Elias Dana | 5 |
#6 | Salitra Yoseph | 5 |
#7 | Gilon Chaim | 4 |
#8 | Levitzki Alexander | 4 |
#9 | Salitra Yosef | 4 |
#10 | Afargan Michel M | 4 |
Publication | Filing date | Title |
---|---|---|
IL174981D0 | Backbone-to-side chain cyclized peptide analogs | |
WO2005072056A2 | Hsp therapy in conjunction with a low antigenicity diet | |
IL164127D0 | Photo-active backbone cyclized somatostatin analogs for photodynamic therapy and imaging | |
EP1575479A2 | Hsp peptides and analogs for modulation of immune responses via antigen presenting cells | |
IL142499A | Building units for synthesis of backbone cyclized peptide analogs | |
IL109943D0 | Conformationally constrained backbone cyclized peptide analogs | |
IL148553A | Backbone cyclized peptide analogs comprising more than one cyclization |